.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Rimegepant is a small-molecule CGRP receptor antagonist that offers an oral alternative to triptan therapy for acute migraine. In this randomized, double-blind, placebo-controlled trial, adults treated a single moderate or severe migraine attack with rimegepant 75 mg or placebo. The coprimary endpoints were freedom from pain and freedom from the patient's most bothersome associated symptom at two hours. The study demonstrated superior efficacy for rimegepant on the prespecified acute-treatment outcomes, while tolerability was generally favourable. The clinical relevance is greatest for patients who need a non-triptan option or who cannot tolerate or appropriately use vasoconstrictive agents. The study also fits the broader evolution of migraine treatment toward mechanism-specific acute therapy. For HCPs, treatment selection should still consider attack frequency, nausea and vomiting, cardiovascular profile, interactions and the distinction between acute and preventive therapy. Rimegepant is not a reason to abandon behavioural strategies or preventive treatment when attacks are frequent. Rather, it broadens the therapeutic toolkit for individualised migraine care. The trial adds controlled evidence to the growing role of CGRP-pathway therapies highlighted in the IANCON programme.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Rimegepant is a small-molecule CGRP receptor antagonist that offers an oral alternative to triptan therapy for acute migraine. In this randomized, double-blind, placebo-controlled trial, adults treated a single moderate or severe migraine attack with rimegepant 75 mg or placebo. The coprimary endpoints were freedom from pain and freedom from the patient's most bothersome associated symptom at two hours. The study demonstrated superior efficacy for rimegepant on the prespecified acute-treatment outcomes, while tolerability was generally favourable. The clinical relevance is greatest for patients who need a non-triptan option or who cannot tolerate or appropriately use vasoconstrictive agents. The study also fits the broader evolution of migraine treatment toward mechanism-specific acute therapy. For HCPs, treatment selection should still consider attack frequency, nausea and vomiting, cardiovascular profile, interactions and the distinction between acute and preventive therapy. Rimegepant is not a reason to abandon behavioural strategies or preventive treatment when attacks are frequent. Rather, it broadens the therapeutic toolkit for individualised migraine care. The trial adds controlled evidence to the growing role of CGRP-pathway therapies highlighted in the IANCON programme.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
3 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
